Products for Research Use Only

SB-265610

CAT: 0804-HY-50688-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-50688-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SB-265610 is a selective, competitive, nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1) -induced calcium mobilization and neutrophil chemotaxis with IC50s of 3.7 nM and 70 nM, respectively[1][2].
CAS Number
211096-49-0
UNSPSC
12352005
Hazard Statement
H302
Target
CXCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
Neuroscience-Neuromodulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/sb-265610.html
Purity
99.0
Solubility
DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
N#CC1=C(N=NN2)C2=C(C=C1)NC(NC(C=CC=C3)=C3Br)=O
Molecular Formula
C14H9BrN6O
Molecular Weight
357.16
Precautions
H302
References & Citations
[1]Auten RL, et al. Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J Pharmacol Exp Ther. 2001 Oct;299 (1) :90-5.|[2]Milatovic S, et al. Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Wound Repair Regen. 2003 May-Jun;11 (3) :213-9.|[3]Li Yang, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008 Jan;13 (1) :23-35.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CXCR2